ANAB
HOLD / NEUTRALMeanRevComposite
49.40
Technical
48.60
Fundamental
49.70
Rank
—
Price
54.92
Hurst
0.23
As of
Sep 22, 2026
Daily
AnaptysBio, Inc.
HealthcareBiotechnologyAnaptysBio is a clinical-stage biotech company developing immunology treatments for autoimmune and inflammatory conditions. Its pipeline includes candidates such as Rosnilimab for rheumatoid arthritis, ANB033 for celiac disease and eosinophilic esophagitis, ANB101 targeting dendritic cells, dostarlimab for solid tumors, and Imsidolimab in Phase 3 testing for generalized pustular psoriasis. The San Diego-based company collaborates with GSK and Vanda on various antibody programs.
Market cap
$1.6B
P/E (trailing)
—
P/E (forward)
9.91
PEG ratio
—
Dividend yield
—
Beta
0.41
52w range
13.81 – 72.36
Return on equity
-114.55%
Profit margin
-11.53%
Revenue growth
—
Earnings growth
—
Price history
1Y: 54.90 (+284.8%) · range 13.97–69.81
Cycle position
43/ 100 cycle scoreMID-BULL
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 34 · NOT READY · exit proximity 0
Conviction
38/ 100 · maturity 14%
VScore.0919
Buildup.3039
EMA entry setup.3834
Fundamentals.2350
Volume profile
POC
55.34
Price vs POC
-0.8%
Overhead supply
60%
Runway
+0.8%
Value area 50.64–65.84 · 60% of 120d volume overhead · heavy supply
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| earnings-surprise | 0.967 | Sep 22, 2026 |
Pattern & cluster
Pattern
NEUTRAL
Cluster
NEUTRALForward returns
Not yet labeled — the study prices these as positions mature.